Exact Therapeutics AS (EXTX) - Net Assets
Based on the latest financial reports, Exact Therapeutics AS (EXTX) has net assets worth Nkr115.55 Million NOK (≈ $12.16 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr153.20 Million ≈ $16.12 Million USD) and total liabilities (Nkr37.65 Million ≈ $3.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Exact Therapeutics AS (EXTX) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr115.55 Million |
| % of Total Assets | 75.42% |
| Annual Growth Rate | 45.55% |
| 5-Year Change | -27.63% |
| 10-Year Change | N/A |
| Growth Volatility | 218.34 |
Exact Therapeutics AS - Net Assets Trend (2017–2024)
This chart illustrates how Exact Therapeutics AS's net assets have evolved over time, based on quarterly financial data. See EXTX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Exact Therapeutics AS (2017–2024)
The table below shows the annual net assets of Exact Therapeutics AS from 2017 to 2024. For live valuation and market cap data, see market value of Exact Therapeutics AS.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr115.55 Million ≈ $12.16 Million |
+156.20% |
| 2023-12-31 | Nkr45.10 Million ≈ $4.75 Million |
-30.73% |
| 2022-12-31 | Nkr65.11 Million ≈ $6.85 Million |
-38.43% |
| 2021-12-31 | Nkr105.74 Million ≈ $11.13 Million |
-33.77% |
| 2020-12-31 | Nkr159.65 Million ≈ $16.80 Million |
+278.00% |
| 2019-12-31 | Nkr42.24 Million ≈ $4.44 Million |
-25.98% |
| 2018-12-31 | Nkr57.06 Million ≈ $6.00 Million |
+583.67% |
| 2017-12-31 | Nkr8.35 Million ≈ $878.27K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Exact Therapeutics AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 787184600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr253.05K | 0.22% |
| Other Components | Nkr115.29 Million | 99.78% |
| Total Equity | Nkr115.55 Million | 100.00% |
Exact Therapeutics AS Competitors by Market Cap
The table below lists competitors of Exact Therapeutics AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CASA DE BUCOVINA-CLUB DE MUNTE
RO:BCM
|
$5.67 Million |
|
Vectus Biosystems Ltd
AU:VBS
|
$5.67 Million |
|
LabGenomics Co. Ltd
KQ:084650
|
$5.67 Million |
|
RH Bophelo Ltd
JSE:RHB
|
$5.67 Million |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
$5.65 Million |
|
Eezy PLC
HE:EEZY
|
$5.65 Million |
|
D.T.C. Industries Public Company Limited
BK:DTCI
|
$5.64 Million |
|
Volato Group Inc.
NYSE MKT:SOAR
|
$5.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exact Therapeutics AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 45,100,880 to 115,546,400, a change of 70,445,520 (156.2%).
- Net loss of 52,331,800 reduced equity.
- Share repurchases of 145,000,000 reduced equity.
- New share issuances of 144,999,996 increased equity.
- Other factors increased equity by 122,777,324.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-52.33 Million | -45.29% |
| Share Repurchases | Nkr145.00 Million | -125.49% |
| Share Issuances | Nkr145.00 Million | +125.49% |
| Other Changes | Nkr122.78 Million | +106.26% |
| Total Change | Nkr- | 156.20% |
Book Value vs Market Value Analysis
This analysis compares Exact Therapeutics AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.05x to 0.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Nkr0.28 | Nkr0.85 | x |
| 2018-12-31 | Nkr1.90 | Nkr0.85 | x |
| 2019-12-31 | Nkr1.41 | Nkr0.85 | x |
| 2020-12-31 | Nkr5.33 | Nkr0.85 | x |
| 2021-12-31 | Nkr3.53 | Nkr0.85 | x |
| 2022-12-31 | Nkr2.17 | Nkr0.85 | x |
| 2023-12-31 | Nkr1.41 | Nkr0.85 | x |
| 2024-12-31 | Nkr1.83 | Nkr0.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exact Therapeutics AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.33x
- Recent ROE (-45.29%) is above the historical average (-49.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -58.87% | 0.00% | 0.00x | 2.40x | Nkr-5.75 Million |
| 2018 | -13.29% | 0.00% | 0.00x | 1.11x | Nkr-13.29 Million |
| 2019 | -35.10% | -16799.67% | 0.00x | 1.23x | Nkr-19.05 Million |
| 2020 | -20.72% | 0.00% | 0.00x | 1.07x | Nkr-49.05 Million |
| 2021 | -55.41% | 0.00% | 0.00x | 1.11x | Nkr-69.16 Million |
| 2022 | -61.60% | 0.00% | 0.00x | 1.27x | Nkr-46.62 Million |
| 2023 | -107.17% | 0.00% | 0.00x | 1.36x | Nkr-52.84 Million |
| 2024 | -45.29% | 0.00% | 0.00x | 1.33x | Nkr-63.89 Million |
Industry Comparison
This section compares Exact Therapeutics AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $212,058,073
- Average return on equity (ROE) among peers: -2095.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exact Therapeutics AS (EXTX) | Nkr115.55 Million | -58.87% | 0.33x | $5.66 Million |
| Arcticzymes Technologies ASA (AZT) | $323.35 Million | 2.62% | 0.06x | $110.17 Million |
| Bergenbio ASA (BGBIO) | $670.23 Million | -38.35% | 0.10x | $7.75 Million |
| Circio Holding ASA (CRNA) | $2.57 Million | -16870.54% | 38.13x | $185.23 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $74.45 Million |
| Nykode Therapeutics ASA (NYKD) | $23.19 Million | -6.92% | 0.08x | $108.24 Million |
| Oncoinvent ASA (ONCIN) | $384.43 Million | -80.47% | 0.17x | $23.56 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $2.37 Million | -1667.07% | 40.09x | $27.77 Million |
| Thor Medical ASA (TRMED) | $337.10 Million | -12.52% | 0.23x | $151.89 Million |
About Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more